Mirion Technologies, Inc.: management transactions · United States · SEC (Form 4)

About Mirion Technologies, Inc.

Mirion Technologies, Inc. (ticker: MIR) is a U.S.-based company listed on the NYSE, in the United States. It is a specialist in radiation detection, measurement, analysis, and monitoring, serving highly regulated end markets where safety, accuracy, and compliance are central to purchasing decisions. For investors, Mirion stands out as a niche industrial technology business with exposure to long-duration themes in nuclear energy, healthcare, and defense. The company is headquartered in Atlanta, Georgia, and reports roughly 2,800 employees across 12 countries, underscoring a meaningful international footprint. Mirion’s current corporate structure was shaped by the business combination completed in October 2021, when GS Acquisition Holdings Corp II was renamed Mirion Technologies, Inc. and the company’s Class A common stock began trading on the NYSE under MIR. While the listed entity is relatively recent, the operating heritage behind Mirion is older and rooted in radiation safety technologies. That history matters: the company operates in a technically demanding field where product reliability, regulatory know-how, and long customer qualification cycles create meaningful barriers to entry. The business is organized into two reportable segments: Medical and Technologies. The Medical segment provides radiation oncology quality assurance, patient safety solutions for diagnostic imaging and radiation therapy centers, dosimetry products to track medical staff exposure, and radionuclide therapy solutions for nuclear medicine applications, including shielding, product handling, and medical imaging furniture. The Technologies segment focuses on defense, nuclear power, laboratories, and research, offering field-ready personal radiation detection and identification devices, along with radiation measurement and analysis tools for the full nuclear power plant lifecycle, including new builds, maintenance, decontamination, decommissioning, and remote environmental monitoring. From a competitive standpoint, Mirion benefits from a specialized product set and customer base that value precision, service continuity, and compliance. Its markets are not immune to capital spending cycles, but they tend to be supported by structural needs such as nuclear safety, healthcare quality, and defense readiness. The company’s broad installed base and technical depth can help support recurring demand for upgrades, replacement, and service-related activity. Geographically, Mirion operates in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. This diversified presence supports both customer proximity and access to major nuclear and medical markets. Recent developments have been notable. Mirion reported first-quarter 2026 results on April 28, 2026. In March 2026, the company announced that its Crew Active Dosimeters would be worn by astronauts on NASA’s Artemis II mission, a high-visibility endorsement of its technology platform. In February 2026, Mirion released fourth-quarter and full-year 2025 results and provided full-year 2026 guidance. In September 2025, it announced a proposed $250 million offering of convertible senior notes due 2031, highlighting active capital-markets management as it continues to invest in growth and strategic flexibility.